USE OF GLP-2 ANALOGUES IN PATIENTS WITH RENAL INSUFFICIENCY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 21, 2024
app pub date -
Dec 15, 2021
filing date -
Dec 16, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), in patients with renal insufficiency. Unlike other GLP-2 analogues, such as teduglutide, it has been found that ZP1848 is cleared normally in patients with renal impairment. As a result, there is no need to adjust the dosage of ZP1848 depending on a patient's renal function.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully